Evidence analysisNovember 13, 2026Health & Science

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

CHMP November 2026 Meeting: New Medicine Recommendations and Therapeutic Extensions

In November 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) conducted its regular meeting and issued a series of recommendations concerning new medicines and extensions of existing treatments. The CHMP’s work directly informs the European Commission decisions on marketing authorisations, which affect drug availability across the European Union.

What is Established

  • The CHMP recommended marketing authorisation for seven new medicines, three of which are for cancer and hypertension treatment, two biosimilars, and two generics.
  • Seven new medicines recommended include:
    • Aumseqa (aumolertinib): for non-small cell lung cancer.
    • Baxfendy (baxdrostat): for adults with insufficiently controlled hypertension.
    • Zybrivo (sintilimab): for non-squamous non-small cell lung cancer in adults.
    • Garzulys and Donrafylix (both insulin aspart): biosimilar insulins for diabetes mellitus starting from 1 year old.
    • Fondaparinux sodium Evumed: generic anticoagulant for prevention and treatment of thromboembolic events and cardiac conditions.
    • Ruxolitinib Krka (ruxolitinib): generic for myelofibrosis, polycythaemia vera, and graft-versus-host disease in adults and children.
  • Eleven medicines received CHMP positive opinions for extending their therapeutic indications, including:
    • Gazyvaro (obinutuzumab): newly recommended for moderate-to-severe active systemic lupus erythematosus (SLE) in adults, notably allowing corticosteroid dose reductions.
    • Isturisa (osilodrostat): expanded use to treat endogenous Cushing’s syndrome in children aged 6 years and above.
    • Additional medicines with extended indications include Bexsero, Cosentyx, Dovato, Enflonsia, Steglatro, Sunlenca, Talzenna, Tivicay, and Welireg.
  • A new formulation strength (100mg) for the Dapivirine Vaginal Ring, an HIV-1 preventive for women, allowing replacement every three months, was given a positive opinion under the EU-Medicines for all (EU-M4All) program, involving experts from multiple African nations and the WHO.
  • The CHMP confirmed refusals for marketing authorisation for two medicines after re-examination:
    • KemSu (sufentanil/ketamine): acute pain in children and adolescents.
    • Meplyffa (arimoclomol citrate): Niemann-Pick disease type C treatment in patients aged two years and older alongside miglustat.
  • Two applications were withdrawn by the applicants:
    • Amlypave (anselamimab): for kappa light chain amyloidosis affecting the heart.
    • Qezzaqar (catequentinib): for two types of soft tissue sarcomas.
  • Significant safety communication regarding Mounjaro (tirzepatide) was issued, warning about potential effects on oral contraceptive reliability, and advising additional contraception methods for women who can become pregnant.

What the Source Claims

The European Medicines Agency presents these recommendations as part of its routine regulatory process to evaluate benefit-risk balance for medicines, facilitating access to new treatments in the EU. The CHMP stresses the importance of addressing unmet patient needs, particularly in oncology, autoimmune diseases, hypertension, and metabolic disorders.

The agency also highlights the collaborative global effort exemplified by the EU-M4All assessment of the Dapivirine Vaginal Ring, emphasizing regulatory capacity-building beyond EU borders.

What May Be Missing from the Usual Framing

  • Clinical Data Details: The summary does not provide detailed clinical trial data supporting these recommendations, such as efficacy endpoints, side effect profiles, or comparative effectiveness versus existing therapies.
  • Patient Population Considerations: There is no discussion on access disparities, affordability, or how these medicines will be integrated into healthcare systems across different EU member states with varying healthcare infrastructures.
  • Withdrawal Reasons: While it is stated that two drug applications were withdrawn, the rationale behind these withdrawals is not provided, leaving uncertainty about whether scientific, commercial, or regulatory issues were dominant.
  • Long-Term Impact and Post-Marketing Surveillance: There is no mention of plans for ongoing monitoring of safety and effectiveness once these medicines enter the market, a crucial aspect especially for new medicines and indications.
  • Conflicts of Interest and Commercial Influence: The reporting does not address potential industry influence or conflicts of interest within the CHMP decision-making process, which historically can shape drug approval landscapes.

Competing Evidence or Uncertainty

Evidence on newer medicines, such as Aumseqa and Baxfendy, is likely emerging and may still be under evaluation elsewhere globally — independent replication of clinical benefits or longer-term safety data may be limited. For biosimilars and generics, issues of interchangeability and real-world efficacy continue to be areas examined post-approval.

Notably, the refusal of marketing authorisation for KemSu and Meplyffa after re-examination indicates regulatory uncertainty or insufficient evidence to meet efficacy or safety standards. This highlights the stringent scrutiny during the approval process but leaves patients and providers without new treatment options in these areas currently.

Moreover, the safety communication about Mounjaro and oral contraceptives points to ongoing pharmacovigilance as a critical component and suggests incomplete understanding of drug-drug interactions in obese or diabetic populations.

Why It Matters

The CHMP’s positive recommendations pave the way for new treatments to become available, addressing significant health challenges such as lung cancer, hypertension, autoimmune disorders, and diabetes. This potentially translates into improved patient outcomes and quality of life.

Approvals of biosimilars and generics are important for healthcare cost-containment and increasing treatment accessibility, key issues given rising healthcare expenses worldwide.

Regulatory decisions also influence pharmaceutical industry investment and research focus areas. The involvement in global regulatory efforts, such as the EU-M4All initiative, promotes international health cooperation and equity.

Safety advisories alert healthcare providers to adjust prescribing practices, mitigating risks for vulnerable populations, a critical function of post-market regulatory vigilance.

What to Verify Next

  • Review publicly available detailed assessment reports or clinical study data behind CHMP recommendations to understand efficacy, safety, and trial populations.
  • Investigate the reasons for withdrawal of Amlypave and Qezzaqar applications through EMA communications or sponsor disclosures.
  • Monitor European Commission decisions following CHMP opinions to confirm which recommendations proceed to marketing authorisation.
  • Track real-world data and post-marketing surveillance outcomes once new medicines enter the market, focusing on safety alerts or unexpected adverse events.
  • Assess how EU member states implement these new treatments in clinical guidelines and reimbursement frameworks, which affect actual patient access.
  • Follow updates on Mounjaro’s safety evaluations to clarify the extent of risk for oral contraceptive users and any additional regulatory action.

Readers interested in more details and ongoing updates should consult the original European Medicines Agency source and official communications from the CHMP and European Commission.

Source & verification

Primary source: News and press releases · November 13, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…